ArticleExperimental and therapeutic medicine2016
Endothelial nitric oxide synthase gene polymorphism is associated with Legg-Calvé-Perthes disease.
Article in Experimental and therapeutic medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- A Proposed Convergent Genetic and Molecular Framework for Legg-Calvé-Perthes Disease: A Scoping Review.International journal of molecular sciences · 2026Review
- Familial Cases of Legg-Calvé-Perthes Disease-Hemostatic and Molecular Markers.International journal of molecular sciences · 2026Article
- Association ofGenes · 2025Article
- Legg-Calvé-Perthes disease- surgical treatment options.Archives of orthopaedic and trauma surgery · 2025Review
- Progress in understanding Legg-Calvé-Perthes disease etiology from a molecular and cellular biology perspective.Frontiers in physiology · 2025Review
- Biochanin A inhibits endothelial dysfunction induced by IL‑6‑stimulated endothelial microparticles in Perthes disease via the NFκB pathway.Experimental and therapeutic medicine · 2024Article
- Prediction of the active compounds and mechanism of Biochanin A in the treatment of Legg-Calvé-Perthes disease based on network pharmacology and molecular docking.BMC complementary medicine and therapies · 2024Article
- Association between Polymorphism eNOS4, tPA, Factor V Leiden, Prothrombin, and Methylenetetrahydrofolate Reductase and the Occurrence of Legg-Calvé-Perthes Disease.Journal of clinical medicine · 2023Article
- Molecular Biomarkers in Perthes Disease: A Review.Diagnostics (Basel, Switzerland) · 2023Review
- Interactions of the eNOS and ACE genes and cigarette smoking in chronic obstructive pulmonary disease.Journal of medical biochemistry · 2023Article
- Legg-Calvé-Perthes disease overview.Orphanet journal of rare diseases · 2022Review
- Microarray analysis of lncRNA and mRNA expression profiles in patients with Legg-Calve-Perthes disease.Frontiers in pediatrics · 2022Article
- Can large doses of glucocorticoids lead to Perthes? a case report and review of the literature.BMC pediatrics · 2021Review
- Is Legg-Calvé-Perthes Disease a Local Manifestation of a Systemic Condition?Clinical orthopaedics and related research · 2018Article
- Association of Nitric Oxide Levels and Endothelial Nitric Oxide Synthase G894T Polymorphism with Coronary Artery Disease in the Iranian Population.Vascular specialist international · 2016Article
- Association of eNOS 27-bp VNTR, 894G>T and 786T>C polymorphisms with susceptibility to Legg-Calve-Perthes Disease in Iranian children.Journal of orthopaedicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to assess the association of 27-bp variable number tandem repeat (VNTR) polymorphism in intron 4 and G894T polymorphism in exon 7 of the endothelial nitric oxide synthase (eNOS) gene with Legg-Calvé-Perthes disease (LCPD), and to provide a scientific basis for further research into the pathogenic mechanism. A total of 80 patients with LCPD and 100 healthy subjects were recruited in this case-control study. The 27-bp VNTR and G894T polymorphisms of the eNOS gene were genotyped using polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism, respectively, followed by agarose gel electrophoresis and DNA sequencing. Allelic and genotypic frequencies were computed in the two groups and subjected to statistical analysis. For the 27-bp VNTR polymorphism, individuals with LCPD showed a higher frequency of the ab genotype [27.5 vs. 14%; odds ratio (OR), 2.33; 95% confidence interval (CI), 1.10-4.92; P=0.024]. For the G894T polymorphism, the LCPD case group showed a higher frequency of the heterozygous genotype GT than the healthy control group (35 vs. 17%; OR, 2.67; 95% CI, 1.33-5.36; P=0.005). The results indicate that these eNOS gene polymorphisms may be a risk factor for LCPD. The 27-bp VNTR polymorphism in intron 4 and G894T polymorphism in exon 7 may be involved in the etiology of LCPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.